signific
progress
achiev
centuri
implement
antiinfect
therapi
improv
qualiti
life
peopl
throughout
world
advanc
also
given
immunocompet
immunosuppress
patient
signific
enhanc
life
span
numer
scientif
lay
public
focus
high
emphasi
problem
antibioticresist
clinic
infect
howev
littl
balanc
discuss
etiolog
impact
subgroup
pathogen
call
biowarfar
agent
contrast
clinicallyrelev
pathogen
biowarfar
agent
intrins
featur
make
etiolog
clinic
treatment
uniqu
featur
rang
product
exotoxin
promot
rapid
organ
failur
anthrax
simpli
lack
small
molecul
therapeut
smallpox
hemorrhag
fever
virus
event
octob
dispers
anthrax
spore
key
us
govern
facil
crippl
function
week
highlight
specter
societ
trauma
due
agent
asid
medic
challeng
effect
public
psych
immeasur
agent
left
impact
histori
civil
natur
distribut
notabl
exampl
smallpox
variola
major
sinc
earli
time
ii
black
death
yersinia
pesti
middl
age
caus
signific
polit
shift
europ
case
especi
hemorrhag
virus
origin
loci
fortuit
third
world
region
epidem
selfextinguish
howev
transocean
travel
facilit
disburs
etiolog
agent
recent
shown
lassa
fever
sever
acut
respiratori
syndrom
sar
biolog
weapon
societ
problem
sinc
first
use
sixth
centuri
bc
middl
age
militari
conflict
agent
intent
dispers
throw
diseas
anim
carcass
opposit
encamp
centuri
sever
notabl
incid
sever
consequ
japanes
dispers
pesti
chines
popul
manchuria
late
ii
accident
releas
anthrax
sverdlovsk
russia
weapon
enhanc
aerosol
agent
biopreparat
soviet
union
biolog
warfar
program
undertook
industrialscal
soviet
weapon
anthrax
tularemia
brucellosi
plagu
typhu
q
fever
smallpox
botulinum
toxin
ebola
marburg
viru
venezuelan
equin
enceph
intent
construct
multiplyresist
mutant
chimer
construct
genet
recombin
dissimilar
agent
individu
resist
mechan
also
cornerston
biopreparat
technolog
agent
virul
multipli
resist
variou
class
therapeut
attain
veepox
combin
venezuelan
equin
enceph
smallpox
frighten
exampl
chimer
construct
start
part
coordin
effort
us
govern
agenc
prepared
event
biowarfar
incid
pathogen
classif
system
adopt
pertin
categori
reproduc
tabl
danger
list
class
agent
rapid
death
class
b
agent
caus
debilit
diseas
slow
death
panic
driven
event
class
pathogen
characterist
medic
oper
challeng
high
morbid
mortal
ii
interperson
transmiss
except
anthrax
tularemia
iii
lack
effect
safe
vaccin
iv
lack
effect
avail
treatment
absenc
pathogen
speciat
data
initi
clinic
symptom
confus
benign
organ
earli
speciat
crucial
lack
small
molecul
therapeut
abundantli
clear
recent
survey
investig
drug
databas
iddb
variou
research
initi
class
agent
show
dearth
small
molecul
lead
highlight
grey
tabl
major
experiment
therapeut
either
vaccin
monoclon
antibodi
class
agent
except
hemorrhag
virus
focu
chapter
research
clinic
knowledg
obtain
class
b
agent
could
provid
new
treatment
modal
clinic
relev
pathogen
exampl
interplay
virul
factor
host
immun
system
could
lead
better
understand
physiolog
sepsi
ii
knowledg
burkholderia
pseudomallei
burkholderia
mallei
could
provid
insight
treatment
burkholderia
cepacia
pulmonari
pathogen
found
patient
cystic
fibrosi
drug
discoveri
effort
biowarfar
agent
list
histor
limit
either
consequ
pathogen
high
prioriti
policymak
agenda
technic
difficulti
technic
difficulti
work
biowarfar
agent
includ
inadequ
knowledg
genom
sequenc
agent
ii
need
use
special
biocontain
facil
iii
inadequ
lack
inlif
model
approxim
human
circumst
iv
also
lack
scientist
relev
research
expertis
clearli
need
new
agent
potent
minim
toxic
biowarfar
agent
synopsi
describ
recent
progress
toward
identifi
small
molecul
inhibitor
anthrax
dimorph
bacterium
normal
exist
spore
clinic
present
cutan
inhal
gastrointestin
form
fortuit
transmiss
person
person
octob
anthrax
case
show
insidi
natur
anthrax
veget
spore
morpholog
veget
state
growth
phase
typic
respons
class
antibiot
spore
phase
thu
long
treatment
modal
system
antibiot
deadli
inhal
form
necessari
order
inhibit
organ
convert
spore
state
veget
state
requir
antiinfect
safeti
profil
adequ
sever
month
administr
major
advanc
would
discoveri
antibiot
effect
spore
phase
stationari
phase
pathogen
second
uniqu
aspect
anthrax
alter
clinic
treatment
presenc
anthrax
toxin
respons
rapid
onset
organ
cardiac
failur
cessat
anthrax
growth
antibiot
action
stop
downstream
biolog
effect
toxin
compon
especi
pathogen
overload
result
larg
titer
anthrax
toxin
releas
bodi
inhal
bacillu
anthraci
spore
germin
alveolar
macrophag
migrat
lymph
node
propag
veget
bacteria
secret
tripartit
toxin
consist
three
protein
lethal
factor
lf
kda
edema
factor
ef
kda
protect
antigen
pa
kda
work
concert
kill
host
cell
modeofact
anthrax
toxin
yet
well
understood
small
molecul
inhibitor
monoclon
antibodi
inhibit
toxin
assembl
andor
function
repres
potenti
use
approach
lethal
factor
lf
zinc
depend
proteas
target
mitogen
activ
protein
kinas
kinas
mapkk
involv
intracellular
signal
pathway
proteas
inactiv
mapkk
signal
mapk
lack
activ
caus
lysi
macrophag
facilit
propag
anthrax
edema
factor
ef
calmodulinmedi
adenyl
cyclas
impair
host
defens
varieti
mechan
inhibit
phagocytosi
includ
interfer
host
immun
respons
facilit
bacteria
propag
induct
massiv
tissu
necrosi
includ
pulmonari
fluid
retent
efcalmodulin
complex
exquisit
potent
hyperact
adenylyl
cyclas
cell
activ
adenyl
cyclas
lose
abil
regul
environ
releas
water
die
protect
antigen
pa
bind
cellular
receptor
tumor
endothelium
upon
bind
pa
cleav
kda
fragment
furin
furinlik
proteas
fragment
reassoci
bind
either
lf
ef
result
complex
intern
endosom
follow
transloc
lf
cytosol
cell
pa
receptor
also
known
anthrax
toxin
receptor
glycoprotein
extracellular
cytosol
tm
domain
nearli
half
pulmonari
anthrax
patient
oct
incid
die
survivor
ongo
symptom
fatigu
short
breath
memori
loss
highlight
need
effect
therapi
variou
initi
ongo
examin
efficaci
exist
antibiot
anthrax
may
address
fear
chimer
construct
anthrax
multiplyresist
variou
class
exist
antibiot
thu
parallel
small
molecul
approach
clinic
use
need
need
new
antibiot
function
new
anthrax
target
also
agent
inhibit
variou
toxin
compon
multipl
biolog
effect
variou
toxin
compon
daunt
even
inhibit
singl
compon
would
benefici
sever
approach
report
potenti
treatment
pulmonari
indic
substitut
investig
inhibitor
lf
smallmolecul
lf
inhibitor
demonstr
vivo
protect
anthrax
toxininduc
diseas
process
also
partial
restor
anthrax
lethal
toxinsuppress
immunolog
function
mice
addit
treat
lethal
toxinexpos
rat
inhibitor
increas
life
span
rat
significantli
examin
subset
nci
compound
librari
research
identifi
inhibitor
lf
common
pharmacophor
may
amen
structur
modif
provid
potent
analog
earlier
screen
lead
peptid
origin
yet
evolv
druglik
molecul
search
new
drug
also
serendipit
use
de
novo
design
strategi
research
univers
chicago
identifi
adefovir
dipivoxil
hepseraw
hepat
b
antivir
vitro
inhibitor
ef
adefovir
fit
time
better
natur
substrat
pocket
surfac
ef
vitro
success
necessarili
translat
vivo
success
new
use
recent
approv
drug
repres
attract
strategi
plagu
caus
bacterium
carri
rodent
flea
current
antibiot
effect
plagu
worri
possibl
bioengin
chimer
construct
would
resist
class
antibiot
wild
rodent
certain
area
around
world
infect
plagu
human
plagu
unit
state
occur
mostli
rural
area
averag
casesannum
vs
case
worldwid
human
case
unit
state
occur
two
region
northern
new
mexico
northern
arizona
southern
colorado
ii
california
southern
oregon
far
western
nevada
plagu
also
exist
africa
asia
south
america
asid
citat
use
older
antibiot
treatment
plagu
one
key
report
molecular
cellular
basi
plagu
virul
attempt
identifi
inhibitor
yersinia
protein
tyrosin
phosphatas
yoph
one
virul
factor
report
activ
aurintricarboxyl
acid
tularemia
tularemia
zoonosi
occur
natur
unit
state
anim
especi
rodent
rabbit
hare
transmiss
man
sometim
insect
vector
may
also
primari
rout
infect
highli
pathogen
inhal
organ
would
adequ
infect
resili
variou
environment
factor
low
temperatur
resid
natur
environ
moist
hay
grass
water
distribut
exist
two
subspeci
f
tularensi
biovar
tularensi
type
ii
f
tularensi
biovar
palaearctica
type
b
type
virul
form
exist
predominantli
north
america
wherea
type
b
less
virul
form
found
europ
asia
aerosol
releas
virul
form
tularemia
would
expect
lead
substanti
morbid
mortal
report
approach
small
molecul
therapi
smallpox
origin
northern
africa
known
ca
year
last
known
case
occur
somalia
declar
erad
histor
caus
death
caus
mortal
smallpox
fear
biowarfar
pathogen
primarili
due
high
transmiss
versu
pathogen
whose
etiolog
affect
episod
eg
pesti
tuberculosi
area
prompt
substanti
interest
last
sever
year
especi
use
vaccinia
virus
surrog
smallpox
number
nucleosid
analog
identifi
inhibit
variou
stage
viral
reproduct
variou
mechan
includ
inosin
monophosph
imp
dehydrogenas
inhibitor
eicar
ii
sadenosylhomocystein
sah
hydrolas
inhibitor
noraristeromycin
neplanocin
analog
iii
orotidin
monophosph
omp
decarboxylas
inhibitor
pyrazofurin
iv
cytidin
triphosph
ctp
synthetas
inhibitor
cyclopentenyl
cytosin
v
thymidyl
synthetas
ts
inhibitor
deoxyuridin
vi
dna
synthetas
inhibitor
araa
vii
acycl
nucleosid
cidofovir
viii
polyacryl
acid
cidofovir
approv
drug
treatment
cytomegaloviru
cmv
infect
potent
inhibitor
smallpox
viru
howev
cidofovir
must
administ
intraven
infus
make
impract
broad
rapid
distribut
event
smallpox
outbreak
patient
parenter
formul
show
nephrotox
event
lipophosph
prodrug
cidofovir
report
oral
bioavail
structur
undisclos
studi
potenti
treatment
smallpox
infect
complic
result
smallpox
vaccin
potent
less
toxic
cidofovir
time
potent
cidofovir
shown
antivir
assay
activ
varieti
pox
virus
includ
smallpox
monkeypox
given
oral
fulli
effect
mous
model
pox
viru
infect
develop
smallpox
therapi
compel
sinc
earlier
clinic
data
regulatori
approv
cmv
indic
would
facilit
use
smallpox
small
molecular
entiti
discuss
review
increas
research
activ
along
enhanc
govern
support
biowarfar
agent
encourag
hope
within
year
signific
develop
small
molecul
discoveri
fill
void
event
conjunct
expand
govern
fund
biowarfar
research
led
shift
antiinfect
research
oper
includ
interest
microbiolog
molecular
microbiolog
adjunct
technolog
increas
academ
institut
especi
evid
use
compar
genom
postgenom
strategi
identifi
pathogen
target
increas
collabor
privat
industri
academ
govern
lab
crystallograph
data
obtain
target
protein
biowarfar
pathogen
massiv
parallel
virtual
screen
effort
encourag
governmentsponsor
program
foster
better
util
governmentsponsor
facil
opportun
research
work
creativ
use
clinicallyrelev
pathogen
surrog
biowarfar
pathogen
b
cereu
b
subtili
b
anthraci
activ
ii
yersinia
pseudotuberculosi
pesti
contrast
tradit
drug
develop
sequenc
requir
phase
iii
studi
fda
creat
new
paradigm
approv
drug
use
biowarfar
agent
new
paradigm
fund
biotech
startup
occur
sever
compani
start
minim
level
ventur
support
substanti
nondilut
govern
fund
iron
one
antiinfect
success
centuri
includ
final
erad
smallpox
somalia
within
one
gener
fear
possibl
use
smallpox
biowarfar
agent
